Trial Clinici

Terza Missione Trial Clinici

2017 Study Code: REDIV/002/17 Protocol Title: "Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized clinical trial (The ROAD trial)" Study promoter: Alfasigma S.p.A Codice Eudract: 2017-002708-28 2018 Study Code: MLN0002-401 -  in corso

Codice EudraCT2017-002708-28 2018
Inizio sperimentazione1 Gennaio 2021

2019 Protocol Title: Relief of heartburn and epigastric pain comparing Neobianacid® with omeprazole: a randomized, double blind, double dummy, reference product controlled, parallel group, non-inferiority clinical study EudraCT number: 2015-005216-15 Study promoter: Aboca S.p.A. Società Agricola,Località Aboca, 20 52037 Sansepolcro Arezzo (Italy) - in corso

Codice EudraCT2015-005216-15
Inizio sperimentazione1 Gennaio 2021